Oracle Health remains the EPR market leader, increasing its NHS EPR market share to 25%, an increase of 1.4% from the year before. System C retains second position despite a 1.4% fall in its market share, while Epic saw the biggest gain, rising by 3.5% to 9.7%. Alcidion, Altera, Meditech and Nervecentr e each gained 0.7% while Dedalus saw a marginal decline of 0.7%, the report also shows. Data from FHI illustrates that c.27% of the 134 existing acute contracts are due to expire within the next 12 months, with a further 8.5% up for renewal in the next three years. While c.24% of trusts either lack an EPR or are out of contract, many of those out of contract are already implementing of procuring new systems, the snapshot report states. One of the key takeaways of the report are that despite the encouraging progress in NHS EPR adoption, challenges remain.